The groundbreaking trial led by Dr. Vinod Balachandran at the Memorial Sloan Kettering Cancer Center (MSK) in New York, showed that half of the patients remained cancer-free 18 months after having their tumors removed and receiving the jabs.
The key to these vaccines appears to be proteins in the pancreatic tumors, called neoantigens, which alert the immune system to keep cancer at bay, according to MSK. The promising results were also presented at the American Society of Clinical Oncology conference in Chicago.
Advertisement
Pancreatic Cancer Clinical Trial
In 8 of 16 patients studied, the vaccines activated T cells that recognize the patient’s own pancreatic cancers. These patients also showed delayed recurrence of their pancreatic cancers, suggesting the T cells activated by the vaccines may be having the desired effect of keeping pancreatic cancers in check.
According to Balachandran, mRNA vaccines could stimulate the immune system to recognize and attack pancreatic cancer cells.
“Unlike some of the other immunotherapies, these mRNA vaccines do appear to have the ability to stimulate immune responses in pancreatic cancer patients,” Balachandran said of the promising preliminary results.
“So we’re very excited about that, and the early results suggest that if you have an immune response, you may have a better outcome.”
Balachandran added the results should be welcome news for other cancer patients too, as pancreatic cancer has been very difficult to treat with traditional chemotherapies and immunotherapies.
The phase-I trial was also heralded as “encouraging” by BioNTech.
“We are committed to taking up this challenge by leveraging our long-standing research in cancer vaccinology and are trying to break new ground in the treatment of such hard-to-treat tumors,” BioNTech co-founder and chief medical officer Prof Ozlem Tureci said.
Source: IANS
